Literature DB >> 15699145

Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins.

Georgia Sfyroera1, Madan Katragadda, Dimitrios Morikis, Stuart N Isaacs, John D Lambris.   

Abstract

Regulation of complement activation by pathogens and the host are critical for survival. Using two highly related orthopoxvirus proteins, the vaccinia and variola (smallpox) virus complement control proteins, which differ by only 11 aa, but differ 1000-fold in their ability to regulate complement activation, we investigated the role of electrostatic potential in predicting functional activity. Electrostatic modeling of the two proteins predicted that altering the vaccinia virus protein to contain the amino acids present in the second short consensus repeat domain of the smallpox protein would result in a vaccinia virus protein with increased complement regulatory activity. Mutagenesis of the vaccinia virus protein confirmed that changing the electrostatic potential of specific regions of the molecule influences its activity and identifies critical residues that result in enhanced function as measured by binding to C3b, inhibition of the alternative pathway of complement activation, and cofactor activity. In addition, we also demonstrate that despite the enhanced activity of the variola virus protein, its cofactor activity in the factor I-mediated degradation of C3b does not result in the cleavage of the alpha' chain of C3b between residues 954-955. Our data have important implications in our understanding of how regulators of complement activation interact with complement, the regulation of the innate immune system, and the rational design of potent complement inhibitors that might be used as therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15699145      PMCID: PMC4138803          DOI: 10.4049/jimmunol.174.4.2143

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  RETRACTED: Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans.

Authors:  K H Murthy; S A Smith; V K Ganesh; K W Judge; N Mullin; P N Barlow; C M Ogata; G J Kotwal
Journal:  Cell       Date:  2001-01-26       Impact factor: 41.582

Review 3.  Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1.

Authors:  D Hourcade; M K Liszewski; M Krych-Goldberg; J P Atkinson
Journal:  Immunopharmacology       Date:  2000-08

4.  DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data.

Authors:  Lee Whitmore; B A Wallace
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

5.  Central modules of the vaccinia virus complement control protein are not in extensive contact.

Authors:  M D Kirkitadze; C Henderson; N C Price; S M Kelly; N P Mullin; J Parkinson; D T Dryden; P N Barlow
Journal:  Biochem J       Date:  1999-11-15       Impact factor: 3.857

6.  Species-specific differences in the structure of orthopoxvirus complement-binding protein.

Authors:  E A Uvarova; S N Shchelkunov
Journal:  Virus Res       Date:  2001-12-04       Impact factor: 3.303

7.  Complementary recognition of alternative pathway activators by decay-accelerating factor and factor H.

Authors:  D Kraus; M E Medof; C Mold
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

8.  Analysis of a large cluster of nonessential genes deleted from a vaccinia virus terminal transposition mutant.

Authors:  G J Kotwal; B Moss
Journal:  Virology       Date:  1988-12       Impact factor: 3.616

9.  Kinetic analysis of the interactions between vaccinia virus complement control protein and human complement proteins C3b and C4b.

Authors:  John Bernet; Jayati Mullick; Yogesh Panse; Pradeep B Parab; Arvind Sahu
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 10.  The relevance of complement to virus biology.

Authors:  Clare E Blue; O Brad Spiller; David J Blackbourn
Journal:  Virology       Date:  2004-02-20       Impact factor: 3.616

View more
  33 in total

1.  Immunophysical properties and prediction of activities for vaccinia virus complement control protein and smallpox inhibitor of complement enzymes using molecular dynamics and electrostatics.

Authors:  Li Zhang; Dimitrios Morikis
Journal:  Biophys J       Date:  2006-02-10       Impact factor: 4.033

Review 2.  Complement evasion by human pathogens.

Authors:  John D Lambris; Daniel Ricklin; Brian V Geisbrecht
Journal:  Nat Rev Microbiol       Date:  2008-02       Impact factor: 60.633

3.  Electrostatic contributions drive the interaction between Staphylococcus aureus protein Efb-C and its complement target C3d.

Authors:  Nurit Haspel; Daniel Ricklin; Brian V Geisbrecht; Lydia E Kavraki; John D Lambris
Journal:  Protein Sci       Date:  2008-08-07       Impact factor: 6.725

4.  Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity.

Authors:  M Kathryn Liszewski; Marilyn K Leung; Richard Hauhart; Celia J Fang; Paula Bertram; John P Atkinson
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

Review 5.  The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins.

Authors:  Brian C DeHaven; Kushol Gupta; Stuart N Isaacs
Journal:  J Gen Virol       Date:  2011-06-29       Impact factor: 3.891

Review 6.  Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.

Authors:  Daniel Ricklin; Edimara S Reis; Dimitrios C Mastellos; Piet Gros; John D Lambris
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

7.  Species Specificity of Vaccinia Virus Complement Control Protein for the Bovine Classical Pathway Is Governed Primarily by Direct Interaction of Its Acidic Residues with Factor I.

Authors:  Jitendra Kumar; Viveka Nand Yadav; Swastik Phulera; Ashish Kamble; Avneesh Kumar Gautam; Hemendra Singh Panwar; Arvind Sahu
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

8.  Cell surface expression of the vaccinia virus complement control protein is mediated by interaction with the viral A56 protein and protects infected cells from complement attack.

Authors:  Natasha M Girgis; Brian C Dehaven; Xin Fan; Kendra M Viner; Mohammad Shamim; Stuart N Isaacs
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

9.  Inhibition of complement and CD14 attenuates the Escherichia coli-induced inflammatory response in porcine whole blood.

Authors:  Ebbe Billmann Thorgersen; Anne Pharo; Karin Haverson; Anne K Axelsen; Peter Gaustad; Girish J Kotwal; Georgia Sfyroera; Tom Eirik Mollnes
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

10.  Anti-inflammatory effects of C1-Inhibitor in porcine and human whole blood are independent of its protease inhibition activity.

Authors:  Ebbe Billmann Thorgersen; Judith K Ludviksen; John D Lambris; Georgia Sfyroera; Erik Waage Nielsen; Tom Eirik Mollnes
Journal:  Innate Immun       Date:  2009-08-26       Impact factor: 2.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.